Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.

Trial Profile

Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2014

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Astrocytoma; Glioma; Oligodendroglioma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 18 Feb 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University: ECOG-E3F05).
    • 07 Dec 2012 New source identified and integrated (Mayo Clinic).
    • 11 Jul 2012 Planned end date changed from 1 Mar 2016 to 1 May 2026 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top